A Phase 1 trial of BP1002 in patients with Non-Hodgkin's Lymphoma
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2017
At a glance
- Drugs BP 1002 (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 06 Nov 2017 According to a Bio-Path Holdings media release, the company expects to initiate this study in 2018.
- 12 Apr 2017 New trial record
- 05 Apr 2017 According to a Bio-Path Holdings media release, company is planning to submit an investigational new drug (IND) application for BP1002 and initiate this trial later in 2017.